EMA Authorised: Aprovel (irbesartan) — Sanofi Winthrop Industrie

View source ↗

Summary

The EMA has authorised Aprovel (irbesartan) by Sanofi Winthrop Industrie for the treatment of hypertension, with decision dated 15 January 2026.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension

Drugs mentioned

• Aprovel (irbesartan)

Snippet

Status: Authorised. Therapeutic area: Hypertension. MAH: Sanofi Winthrop Industrie. Decision date: 15/01/2026